In summary our data support the use of therapeutic approaches based on Erk2 inhibition, which could be added to the therapeutic armamentarium to fight CML, especially when IM resistance develops secondary to Erk2 activation. The gene discussed is MAPK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.